RATIONALE: Hereditary angioedema (HAE) results from a deficiency of C1 esterase inhibitor, allowing for excessive conversion of prekallikrein (PK) into plasma kallikrein. Lanadelumab specifically inhibits plasma kallikrein, and prevented HAE attacks in the HELP Study (NCT02586805). Plasma kallikrein contributes to the aPTT coagulation test; therefore, a prolonged aPTT is an expected effect of lanadelumab. No effect on prothrombin time (PT) is expected. We evaluated the effects of lanadelumab on coagulation parameters in HAE patients. METHODS: Patients > _12 years old with type I/II HAE and > _1 attack during a 4-week run-in received subcutaneous lanadelumab 150mg q4wks, 300mg q4wks, 300mg q2wks, or placebo over 26 weeks. Coagulation testing was performed at screening and throughout the study using standard laboratory tests. 27.1562.857s (21.4-33.9) with placebo. These data show the prolongation in aPTT assay with lanadelumab as expected. PT was not altered. CONCLUSIONS: These data indicate that lanadelumab prolonged aPTT in treated groups, but not outside the normal range and with no association with abnormal bleeding events. Based on these data, lanadelumab inhibition of plasma kallikrein activity is sufficient for effective HAE prophylaxis without alteration of hemostasis or thrombosis in vivo. (NONMEM v7.3). The previously developed model was used to describe the PK of C1-INH(f) after subcutaneous administration of C1-INH to HAE patients. Several PD models were tested to describe the relationship between C1-INH(f) and C4 antigen concentrations. RESULTS: A positive linear relationship was observed between C4 antigen concentrations and C1-INH(f) in type I and II HAE patients based on the Loess fit until C1-INH(f) of ;50%, at which point signs of saturation were apparent. A mechanistic quantification of this relationship was established with the indirect response model with C1-INH causing inhibition of the loss of C4 (rate of loss5 k out ) showing best performance in data characterization. Baseline C4 antigen concentration was estimated at 7.52 mg/dL (29.4% inter-individual variability). The IC 50 was estimated at 56.3% C1-INH. No covariates were found to be significant to describe the parameter variability. CONCLUSIONS: The relationship between C1-INH(f) and C4 antigen concentrations in HAE patients was adequately described by a mechanistically accurate indirect response model with inhibition of removal process.
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